A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MOXR0916 ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT TO PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
This is a first-in-human, Phase I, open-label, multicentre, dose-escalation study designed
to evaluate the safety, tolerability, and pharmacokinetics of MOXR0916 administered
intravenously in patients with locally advanced or metastatic solid tumours that have
progressed after all available standard therapy or for which standard therapy has proven to
be ineffective or intolerable, or is considered inappropriate. The planned duration of the
study is approximately 3 years.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society